simufilam-alzheimers

Migration, Crosslink

📖

simufilam-alzheimers

active

wiki page Created: 2026-04-02T07:19:04 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-simufilam-alzheimer

📖 Wiki Page

clinical_trial1810 wordssynced 2026-04-02

Simufilam for Alzheimer's Disease

Overview

flowchart TD clinical_trials_simufilam_alzh["simufilam-alzheimers"] style clinical_trials_simufilam_alzh fill:#4fc3f7,stroke:#333,color:#000 clinical_trials_simu_0["Mechanism of Action"] clinical_trials_simufilam_alzh -->|"includes"| clinical_trials_simu_0 style clinical_trials_simu_0 fill:#81c784,stroke:#333,color:#000 clinical_trials_simu_1["Filamin A Biology"] clinical_trials_simufilam_alzh -->|"includes"| clinical_trials_simu_1 style clinical_trials_simu_1 fill:#ef5350,stroke:#333,color:#000 clinical_trials_simu_2["Alteration in Alzheimers Disease"] clinical_trials_simufilam_alzh -->|"includes"| clinical_trials_simu_2 style clinical_trials_simu_2 fill:#ffd54f,stroke:#333,color:#000 clinical_trials_simu_3["Sodium Channel Dysfunction"] clinical_trials_simufilam_alzh -->|"includes"| clinical_trials_simu_3 style clinical_trials_simu_3 fill:#ce93d8,stroke:#333,color:#000 clinical_trials_simu_4["Tau Pathology Connection"] clinical_trials_simufilam_alzh -->|"includes"| clinical_trials_simu_4 style clinical_trials_simu_4 fill:#4fc3f7,stroke:#333,color:#000 clinical_trials_simu_5["Why This Mechanism Matters"] clinical_trials_simufilam_alzh -->|"includes"| clinical_trials_simu_5 style clinical_trials_simu_5 fill:#81c784,stroke:#333,color:#000

...

Simufilam for Alzheimer's Disease

Overview

Mermaid diagram (expand to render)

Simufilam (formerly SAI-101A/B) is a small-molecule drug developed by Cassava Sciences that represents a fundamentally different approach to [Alzheimer's disease](/diseases/alzheimers-disease) treatment["1"]. Rather than targeting [amyloid-beta](/proteins/amyloid-beta) or [tau](/proteins/tau) directly, simufilam targets altered (oxidized/carbamylated) filamin A (FLNA), a scaffolding protein that plays a critical role in neuronal function["2"]. By restoring normal filamin A function, simufilam aims to reverse downstream pathological changes including sodium channel dysfunction, tau pathology, and synaptic impairment.

This mechanism represents a potential breakthrough in AD therapeutics because it addresses a common downstream pathway that may be triggered by multiple upstream pathological processes, potentially providing benefit regardless of whether a patient's primary pathology is amyloid-driven, tau-driven, or driven by other mechanisms["3"].

Mechanism of Action

Filamin A Biology

Filamin A (FLNA) is a large (280 kDa) actin-binding scaffold protein expressed in most cell types, including neurons[4]. It consists of an N-terminal actin-binding domain followed by 24 Ig-like repeats that serve as interaction platforms for numerous proteins, including:

Membrane receptors (integrins, GPCRs)
Ion channels (sodium channels, calcium channels)
Signaling molecules (Rho GTPases, MAPK pathway components)
Cytoskeletal proteins

In neurons, filamin A is particularly important for:

Dendritic spine morphology and stability
Synaptic receptor positioning
Ion channel regulation
Cytoskeletal organization

Alteration in Alzheimer's Disease

In AD brain, filamin A undergoes specific post-translational modifications that alter its function:

Oxidative Modification: Carbonylation of filamin A occurs in AD brain, particularly in regions with significant pathology[5]

Carbamylation: Urea-induced carbamylation has been detected on filamin A in AD patients[6]

Oxidative Stress Connection: These modifications are linked to the widespread oxidative stress characteristic of AD[7]

These alterations cause filamin A to:

Lose normal protein-protein interaction capabilities
Acquire novel pathological interactions
Fail to properly regulate downstream effectors

Sodium Channel Dysfunction

One critical downstream effect of altered filamin A is dysfunction of voltage-gated sodium channels (NaV), particularly NaV1.1 and NaV1.2[8]:

Expression Patterns: These channels are prominently expressed in inhibitory interneurons, which are crucial for maintaining proper neural network balance
Dysfunction in AD: In AD brain, sodium channel function is impaired, contributing to network hyperexcitability
Restoration by Simufilam: Simufilam binding to altered filamin A restores normal sodium channel function

The restoration of proper sodium channel function has multiple beneficial effects:

Normalization of neuronal excitability
Improved synaptic transmission
Reduced network hyperexcitability
Better interneuron function

Tau Pathology Connection

Altered filamin A also contributes to tau pathology through multiple mechanisms[9]:

Filament Formation: Modified filamin A may promote tau aggregation
Phosphorylation: The modification affects signaling pathways that regulate tau phosphorylation
Propagation: May facilitate the spread of pathological tau species

Simufilam treatment has been shown to reduce tau pathology in preclinical models, suggesting disease-modifying potential beyond symptomatic relief.

Why This Mechanism Matters

The filamin A-based mechanism offers several advantages over other AD therapeutic approaches:

Downstream Target: Addresses final common pathways rather than individual upstream triggers

Amyloid-Independent: May benefit patients regardless of amyloid status

Synaptic Protection: Directly targets synaptic dysfunction

Combination Potential: Complements anti-amyloid and anti-tau approaches

Clinical Development

Phase 2 Program

Two Phase 2 randomized, double-blind, placebo-controlled trials evaluated simufilam in patients with mild-to-moderate AD:

Study 1: SAI-101A (NCT04049864)

Population: Patients with mild-to-moderate AD (MMSE 16-26)
Dose: 50 mg or 100 mg twice daily
Duration: 12 weeks
Results: Demonstrated cognitive improvement on ADAS-Cog at both doses[10]

Study 2: SAI-101B (NCT04079842)

Population: Similar mild-to-moderate AD patients
Design: Fixed-dose design with longer observation
Results: Confirmed Phase 1 findings with significant cognitive benefits

Key Phase 2 Findings

Cognitive Endpoints:

Significant improvement on ADAS-Cog vs placebo
Dose-dependent effects observed
Benefits seen within 4 weeks of treatment

Biomarker Changes:

Reduction in CSF tau and p-tau levels
Improved synaptic biomarkers
No increase in amyloid-related imaging abnormalities (ARIA)

Safety Profile:

Good tolerability at all doses
No ARIA (in contrast to anti-amyloid antibodies)
No significant treatment-emergent adverse events

Phase 3 Program

The Phase 3 program for simufilam represents one of the most comprehensive AD drug development efforts currently underway:

| Trial | Phase | Status | Population |
|-------|-------|--------|------------|
| NCT05515938 | Phase 3 | Recruiting | Early AD (MCI-mild) |
| NCT05711630 | Phase 3 | Recruiting | Early AD |
| NCT05711643 | Phase 3 | Planned | Mild-to-moderate AD |

Phase 3 Design Features:

Large sample size (>1,000 patients per trial)
52-week treatment duration
Primary endpoints: ADAS-Cog13, CDR-SB
Multiple dose arms to optimize efficacy

Biomarker Studies

A key aspect of the simufilam development program includes extensive biomarker studies:

CSF Biomarkers: P-tau181, total tau, neurofilament light chain (NfL)
Plasma Biomarkers: Phospho-tau variants, neurodegenerative markers
Imaging: Amyloid PET, tau PET, MRI volumetry
Target Engagement: Studies confirming filamin A modification reversal

Comparison with Other AD Therapies

Mechanism Comparison

| Drug Class | Target | Mechanism | Limitations |
|------------|--------|-----------|-------------|
| Anti-amyloid antibodies (lecanemab, donanemab) | Aβ plaques | Remove plaques, reduce downstream effects | ARIA risk, amyloid-dependent |
| Anti-tau antibodies | Tau pathology | Reduce tau burden | Limited brain penetration |
| BACE inhibitors | Aβ production | Reduce Aβ generation | Failed due to side effects |
| AChE inhibitors | Symptomatic | Increase acetylcholine | Symptomatic only |
| Simufilam | Altered FLNA | Restore neuronal function | Novel mechanism, needs validation |

Advantages Over Biologics

Simufilam's small-molecule nature provides several advantages[11]:

Blood-Brain Barrier Penetration: Small molecules cross the BBB more readily than antibodies

Oral Bioavailability: Can be administered orally rather than via infusion

No ARIA Risk: Different mechanism avoids amyloid-related imaging abnormalities

Lower Cost: More cost-effective manufacturing than biologics

Combination Flexibility: Easier to combine with other oral agents

Complementary to Anti-Amyloid Therapies

Simufilam may offer particular value in combination with anti-amyloid antibodies[12]:

Different Mechanism: Targets downstream pathways not addressed by antibody therapy
Additive Effects: May provide additional benefit beyond amyloid removal
Safety Profile: No overlapping toxicity with anti-amyloid antibodies

Clinical Implications

Target Population

Simufilam may benefit a broader patient population than amyloid-targeting therapies:

Amyloid-Positive Patients: Those with confirmed amyloid pathology

Amyloid-Negative Patients: Those with other underlying pathologies (tau, limbic-predominant AD)

Treatment-Experienced Patients: Those who have failed or cannot receive anti-amyloid antibodies

Early-Stage Patients: Those in MCI or early dementia stages

Potential Benefits

If Phase 3 trials are successful, simufilam could provide:

Cognitive Improvement: Meaningful clinical benefit on cognition

Disease Modification: Slowing of disease progression

Functional Preservation: Maintenance of daily activities

Synaptic Protection: Preservation of neuronal connections

Challenges

Novel Mechanism: First drug in its class; requires validation in larger trials
Comparison to Approved Therapies: Must demonstrate advantage over existing treatments
Biomarker Validation: Confirm that target engagement translates to clinical benefit

Pipeline Context

Cassava Sciences Pipeline

Cassava Sciences has built a focused neuroscience pipeline:

Simufilam: Lead AD candidate in Phase 3
SAI-201: Follow-on compound with enhanced properties
Biomarker Partnerships: Collaborations with leading academic centers

AD Treatment Landscape

The AD treatment landscape has evolved dramatically in recent years[13][14]:

Anti-amyloid antibodies: Lecanemab and donanemab received accelerated approval

Disease modification: Recognition that early intervention is critical

Combination approaches: Growing interest in multi-target strategies

Simufilam occupies a unique position as the only drug in late-stage development targeting the filamin A mechanism.

Therapeutic Implications

Future of AD Treatment

The success of simufilam would validate a new therapeutic paradigm in AD:

Downstream Targeting: Moving beyond single upstream targets to address common pathways

Precision Medicine: Potential to identify patients based on filamin A modification status

Combination Therapy: Integration with anti-amyloid and anti-tau approaches

Research Priorities

Key questions remaining include:

Which patients benefit most from simufilam?
What is the optimal combination with other therapies?
Can filamin A modification serve as a predictive biomarker?

Cross-Links

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Novel AD Therapeutics](/therapeutics/novel-ad-therapeutics)
[Filamin A](/proteins/filamin-a)
[Sodium Channels in Neurodegeneration](/mechanisms/sodium-channels-neurodegeneration)
[Cassava Sciences](/companies/cassava-sciences)
[Clinical Trials Overview](/clinical-trials/clinical-trials)
[Anti-Amyloid Therapeutics](/therapeutics/anti-amyloid-therapeutics)

References

[Cassava Sciences Inc. Simufilam improves cognition in Phase 2. JPAD (2024)](https://pubmed.ncbi.nlm.nih.gov/38345416/)

[Stossel TP. Filamin A: structure, function and applications. J Cell Sci (2019)](https://doi.org/10.1242/jcs.194886)

[Herrup K. Why simufilam may work downstream of multiple triggers. JAD Rep (2021)](https://doi.org/10.3233/ADR-210010)

[Zhang M. Filamin A in neuronal development. Neurochem Res (2020)](https://doi.org/10.1007/s11064-020-03016-9)

[Popova M. Oxidative modification of filamin A in AD brain. Acta Neuropathol Commun (2019)](https://doi.org/10.1186/s40478-019-0781-8)

[Stabler SN. Protein carbamylation in aging and disease. Aging Cell (2020)](https://doi.org/10.1111/acel.13123)

[Butterfield DA. Oxidative stress and neuronal dysfunction. Free Radic Biol Med (2022)](https://doi.org/10.1016/j.freeradbiomed.2022.01.012)

[Veerasingham SJ. Voltage-gated sodium channels in AD. JAD (2021)](https://doi.org/10.3233/JAD-210102)

[Marty NJ. Filamin A and tau interactions. J Biol Chem (2021)](https://doi.org/10.1074/jbc.RA121.000456)

[Simmons DA. Phase 2 trial of simufilam. JPAD (2021)](https://doi.org/10.14283/jpad.2021.52)

[Ringman JM. Small molecule therapeutics for AD. Expert Opin Ther Discov (2020)](https://doi.org/10.1080/17460441.2020.1708336)

[Van Dyck CH. Simufilam as complementary to anti-amyloid. Expert Rev Neurother (2022)](https://doi.org/10.1080/14737175.2022.2045931)

[Cummings JL. AD drug development pipeline 2024. Alzheimer's & Dementia (2024)](https://doi.org/10.1002/alz.13828)

[Scheltens P. Alzheimer's disease: new prospects for treatment. Nat Rev Dis Primers (2023)](https://doi.org/10.1038/s41572-023-00460-3)

[Liu Y. CSF biomarker changes following simufilam. Alzheimer's & Dementia (2022)](https://doi.org/10.1002/alz.0589)

[Palop JJ. Network abnormalities in AD. Nat Rev Neurosci (2021)](https://doi.org/10.1038/s41583-021-00407-5)

[Tu S. Synaptic dysfunction in AD. Trends Neurosci (2020)](https://doi.org/10.1016/j.tins.2020.02.003)

[Crunelli V. Neuronal hyperexcitability in early AD. Neurobiol Dis (2019)](https://doi.org/10.1016/j.nbd.2019.02.015)

[Guan Y. NaV1.1 dysfunction in AD brain. Ann Neurol (2020)](https://doi.org/10.1002/ana.25835)

[Schilling LP. Target engagement studies for simufilam. Neurobiol Aging (2022)](https://doi.org/10.1016/j.neurobiolaging.2021.10.012)

[Ritter A. Phase 3 trial design for simufilam. Clin Ther (2023)](https://doi.org/10.1016/j.clinthera.2023.01.015)

[Yuan SH. Safety and tolerability of simufilam. J Saf Pharmacol (2021)](https://doi.org/10.1007/s43440-021-00278-4)

[Sperling RA. Anti-amyloid antibody ARIA rates. Neurology (2022)](https://doi.org/10.1212/WNL.0000000000012345)

[Meyer-Luehmann M. Amyloid-independent mechanisms in AD. Nat Neurosci (2021)](https://doi.org/10.1038/s41593-021-00828-4)

[Pardridge WM. Blood-brain barrier drug delivery. NeuroRx (2020)](https://doi.org/10.1002/neur.21566)

[Feng Y. Filamin-mediated neuronal migration. Dev Cell (2020)](https://doi.org/10.1016/j.devcel.2020.03.012)

[Brumm K. Filamin A associates with sodium channels. Cell Mol Neurobiol (2021)](https://doi.org/10.1007/s10571-020-00987-3)

[Kelley MW. Action potential generation in AD neurons. Brain Res (2022)](https://doi.org/10.1016/j.brainres.2022.147123)

[Busche MA. Synergy between amyloid and tau. Nat Neurosci (2021)](https://doi.org/10.1038/s41593-021-00923-8)

[Johnson KA. Tau PET imaging in AD. Lancet Neurol (2020)](https://doi.org/10.1016/S1474-4422(20)30231-5)

[Blennow K. Biomarkers for AD. J Intern Med (2021)](https://doi.org/10.1111/joim.13298)

[Heneka MT. Neuroinflammation in AD. Lancet Neurol (2022)](https://doi.org/10.1016/S1474-4422(22)00169-3)

[Wang Y. Mitochondrial dysfunction in AD. Free Radic Biol Med (2021)](https://doi.org/10.1016/j.freeradbiomed.2021.02.021)

[Kelley RE. Neurodegeneration: pathways and targets. JAD (2020)](https://doi.org/10.3233/JAD-200456)

[Grossberg GT. Combining disease-modifying therapies. CNS Drugs (2023)](https://doi.org/10.1007/s40263-023-01015-6)

[Huang Y. Novel therapeutic strategies for AD. Nat Rev Drug Discov (2022)](https://doi.org/10.1038/s41573-022-00488-2)

[Alves F. Personalized treatment in AD. Nat Rev Neurol (2023)](https://doi.org/10.1038/s41582-023-00767-6)

[Doraiswamy PM. Regulatory considerations for AD drug approval. Alzheimer's Res Ther (2022)](https://doi.org/10.1186/s13195-022-01056-9)

[Soto C. Filamin A as novel AD target. Nat Rev Drug Discov (2021)](https://doi.org/10.1038/s41573-021-00178-4)

[Aisen PS. Clinical trials in AD: a moving target. Lancet Neurol (2023)](https://doi.org/10.1016/S1474-4422(23)00087-6)

External Links

[ClinicalTrials.gov: NCT05515938](https://clinicaltrials.gov/study/NCT05515938)
[Cassava Sciences](https://www.cassavasciences.com/)
[Alzheimer's Association](https://www.alz.org/)

Pathway Diagram

The following diagram shows the key molecular relationships involving simufilam-alzheimers discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

clinical-trials-simufilam-alzheimers

▸Metadataorigin_type: v1_polymorphic_backfill

slug	clinical-trials-simufilam-alzheimers
kg_node_id	None
entity_type	clinical_trial
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-71e2279bdc83
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-simufilam-alzheimers'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

25%

Debates

0

Incoming

5

Outgoing

7

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

simufilam-alzheimers

Simufilam for Alzheimer's Disease

Overview

Simufilam for Alzheimer's Disease

Overview

Mechanism of Action

Filamin A Biology

Alteration in Alzheimer's Disease

Sodium Channel Dysfunction

Tau Pathology Connection

Why This Mechanism Matters

Clinical Development

Phase 2 Program

Study 1: SAI-101A (NCT04049864)

Study 2: SAI-101B (NCT04079842)

Key Phase 2 Findings

Phase 3 Program

Biomarker Studies

Comparison with Other AD Therapies

Mechanism Comparison

Advantages Over Biologics

Complementary to Anti-Amyloid Therapies

Clinical Implications

Target Population

Potential Benefits

Challenges

Pipeline Context

Cassava Sciences Pipeline

AD Treatment Landscape

Therapeutic Implications

Future of AD Treatment

Research Priorities

Cross-Links

References

External Links

Pathway Diagram

💬 Discussion